Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial [0.03%]
降糖药物疗效的比较：利用真实世界数据模拟四组目标临床试验
Ali Ahmed,Stefan D Anker,Javed Butler et al.
Ali Ahmed et al.
Challenges in implementing nationwide epidemiological studies on metabolic non-communicable diseases in low-income and middle-income countries [0.03%]
发展中国家开展全国范围代谢性非传染性疾病流行病学研究的挑战
Ranjit Mohan Anjana,Nirmal Elangovan,Rajendra Pradeepa et al.
Ranjit Mohan Anjana et al.
Gernot Desoye,Mireille van Poppel
Gernot Desoye
The Lancet Diabetes & Endocrinology Commission on type 1 diabetes: looking back to move forward [0.03%]
lancet糖尿病及内分泌疾病委员会第1型糖尿病：回顾过去展望未来
David Beran,Marta Koch,Sana Ajmal et al.
David Beran et al.
The Lancet Diabetes Endocrinology
The Lancet Diabetes Endocrinology
Catecholamine-induced hypertensive crises: current insights and management [0.03%]
儿茶酚胺所致高血压危象：当前见解及处理方法
Matthew A Nazari,Rockyb Hasan,Mark Haigney et al.
Matthew A Nazari et al.
Phaeochromocytomas and paragangliomas (PPGLs) release catecholamines leading to catecholamine-induced hypertensive (CIH) crises, with blood pressure greater than or equal to 180/120 mm Hg. CIH crises can be complicated by tachyarrhythmias, ...
C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis [0.03%]
新发1型糖尿病的疾病修正疗法临床试验中的C肽与代谢结局：个体参与者meta分析
Peter N Taylor,Kimberly S Collins,Anna Lam et al.
Peter N Taylor et al.
Background: Metabolic outcomes in type 1 diabetes remain suboptimal. Disease modifying therapy to prevent β-cell loss presents an alternative treatment framework but the effect on metabolic outcomes is unclear. We, there...
Tackling the diabetes surge in sub-Saharan Africa through novel youth-centric strategies [0.03%]
通过创新的青年中心策略应对撒哈拉以南非洲糖尿病激增
Felix P Chilunga,Asanda Mtintsilana,Pearl Aovare et al.
Felix P Chilunga et al.